ASP Isotopes Inc.
Description
ASP Isotopes Inc., a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc. was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
About
CEO
Mr. Paul Elliot Mann C.F.A.
Employees
76
Instrument type
Common Stock
Sector
Basic Materials
Industry
Chemicals
MIC code
XNCM
Address
1101 Pennsylvania Avenue NW, Washington, DC 20004, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 20, 2024 | -0.09 | -0.12 | -0.03 | 33.33% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 1 |
| Average estimate | — | -0.06 | — | -0.15 |
| Low estimate | — | -0.06 | — | -0.15 |
| High estimate | — | -0.06 | — | -0.15 |
| Last year EPS | — | — | — | -0.57 |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year
—
Next year (Dec 2025)
73.680%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | |
|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 |
| Total reported revenue | 433,026 | — |
| Cost of revenue | 294,056 | — |
| Gross profit | 138,970 | — |
| Operating expense | ||
| Research & development | 764,581 | 1.27M |
| Selling general and admin | 15.42M | 3.83M |
| Other operating expenses | — | — |
| Operating income | -16.04M | -5.10M |
| Non operating interest income | ||
| Income | 9,074 | 3,382 |
| Expense | 118,547 | — |
| Other income expense | -148,787 | 150,527 |
| Pretax income | -16.30M | -4.95M |
| Tax provision | -6,133 | — |
| Net income | -16.29M | -4.95M |
| Basic EPS | -0.49 | -0.18 |
| Diluted EPS | -0.49 | -0.18 |
| Basic average shares | 33.07M | 26.79M |
| Diluted average shares | 33.07M | 26.79M |
| EBITDA | -16.19M | -4.95M |
| Net income from continuing op. | -16.29M | -4.95M |
| Minority interests | 7,892 | — |
| Preferred stock dividends | — | — |
Balance sheet
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 27.54M | 12.50M | 7.14M |
| Current assets | |||
| Cash | 7.91M | 2.39M | 2.95M |
| Cash equivalents | — | — | — |
| Cash and cash equivalents | 7.91M | 2.39M | 2.95M |
| Other short term investments | — | — | — |
| Accounts receivable | 216,504 | — | — |
| Other receivables | — | — | — |
| Inventory | — | — | — |
| Prepaid assets | — | — | 267,562 |
| Restricted cash | — | — | — |
| Assets held for sale | — | — | — |
| Hedging assets | — | — | — |
| Other current assets | 1.66M | 913,005 | 267,562 |
| Non current assets | |||
| Properties | 1.26M | 853,889 | 933,145 |
| Land and improvements | — | — | — |
| Machinery furniture equipment | 1.62M | — | — |
| Construction in progress | 9.11M | 8.20M | 2.99M |
| Leases | 21,446 | — | — |
| Accumulated depreciation | -37,707 | — | — |
| Goodwill | 6.53M | — | — |
| Investment properties | — | — | — |
| Financial assets | — | — | — |
| Intangible assets | — | — | — |
| Investments and advances | — | — | — |
| Other non current assets | 1.79M | 139,636 | — |
| Total liabilities | 8.71M | 2.68M | 1.14M |
| Current liabilities | |||
| Accounts payable | 1.11M | 1.35M | 59,679 |
| Accrued expenses | 1.31M | 361,246 | 42,500 |
| Short term debt | 868,901 | 79,757 | 84,972 |
| Deferred revenue | 882,000 | — | — |
| Tax payable | — | — | — |
| Pensions | — | — | — |
| Other current liabilities | 1.50M | 140,455 | 116,200 |
| Non current liabilities | |||
| Long term debt | 1.27M | 742,443 | 841,623 |
| Provision for risks and charges | — | — | — |
| Deferred liabilities | 110,578 | — | — |
| Derivative product liabilities | — | — | — |
| Other non current liabilities | 1.65M | — | — |
| Shareholders equity | |||
| Common stock | 489,233 | 359,071 | 206,525 |
| Retained earnings | -23.84M | -7.55M | -2.61M |
| Other shareholders equity | -920,982 | 255,030 | 18,723 |
| Total shareholders equity | 18.83M | 9.82M | 6.00M |
| Additional paid in capital | 40.57M | 16.76M | 8.38M |
| Treasury stock | — | — | — |
| Minority interest | 2.53M | — | — |
Cash flow statement
| 2023 | 2022 | |
|---|---|---|
| Operating Activities | ||
| Net Income | -16.29M | -4.95M |
| Depreciation | 37,433 | — |
| Deferred Taxes | 16,655 | — |
| Stock-Based Compensation | 8.74M | 2.00M |
| Other Non-Cash Items | 774,228 | 122,570 |
| Accounts Receivable | 237,952 | — |
| Accounts Payable | -224,598 | 570,600 |
| Other Assets & Liabilities | 841,553 | -183,834 |
| Operating Cash Flow | -5.87M | -2.44M |
| Investing Activities | ||
| Capital Expenditures | -2.33M | -4.47M |
| Net Intangibles | — | — |
| Net Acquisitions | -121,848 | — |
| Purchase of Investments | — | — |
| Sale of Investments | — | — |
| Investing Cash Flow | -2.45M | -4.47M |
| Financing Activities | ||
| Long-Term Debt Issuance | — | — |
| Long-Term Debt Payments | -706,813 | -13,046 |
| Other Financing Charges | -563,473 | -1.47M |
| Financing Cash Flow | 12.69M | 6.64M |
| Other Cash Details | ||
| End Cash Position | 7.91M | 2.39M |
| Income Tax Paid | — | — |
| Interest Paid | — | — |
| Free Cash Flow | -7.74M | -7.41M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,508,843 | 9.17M | 2.11% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,448,603 | 8.81M | 2.03% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 871,052 | 5.30M | 1.22% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 513,469 | 3.12M | 0.72% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 451,993 | 2.75M | 0.63% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 283,331 | 1.72M | 0.40% |
| Vanguard Russell 2000 Index Fund | Nov 30, 2024 | 239,374 | 1.46M | 0.34% |
| Vanguard U.S. Momentum Factor ETF | Nov 30, 2024 | 202,061 | 1.23M | 0.28% |
| Schwab Capital Trust-Small Cap Index Fund | Oct 31, 2024 | 120,278 | 731,290 | 0.17% |
| iShares Micro Cap ETF | Nov 30, 2024 | 116,289 | 707,037 | 0.16% |
Article
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ASP Isotopes Inc. (ASPI) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
Feb 9, 2025
Article
Bronstein, Gewirtz & Grossman, LLC Encourages ASP Isotopes Inc. (ASPI) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
Feb 6, 2025
Article
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ASP Isotopes Inc. (ASPI) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
Feb 4, 2025
